Skip to main content

Table 2 Baseline values of outcome measures

From: Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]

  Fluvoxamine (n = 17) Placebo (n = 16) P-value
VAS Fatigue 7.40 7.45 0.91
VAS Pruritus 3.50 1.15 0.33
Beck Depression Inventory 11.0 10.5 0.45
FFSS
   Physical Domain 24.0 16.5 0.25
   Cognitive Domain 15.0 9.0 0.04
   Social Domain 37.0 22.5 0.04
MFI
   General Fatigue 18.0 17.5 0.78
   Physical Fatigue 16.0 14.0 0.22
   Reduction in Activity 15.0 13.0 0.30
   Reduction in Motivation 13.0 10.0 0.17
   Mental Fatigue 13.0 13.0 0.90
SF-36
   Physical Functioning 65.0 70.0 0.47
   Role Functioning Physical 25.0 25.0 0.35
   Bodily Pain 62.0 62.0 0.55
   General Health 40.0 35.0 0.63
   Vitality 45.0 40.0 0.64
   Social Functioning 62.5 62.5 0.34
   Role Emotional Functioning 100.0 66.7 0.46
   Mental Health 56.0 60.0 0.28
   Reported Health Transition 4.0 4.0 1.00
  1. All results are expressed as median scores.